共 60 条
[1]
Navari RM(2017)Management of chemotherapy-induced nausea and vomiting in pediatric patients Paediatric drugs 19 213-222
[2]
Aapro M(2015)Aprepitant and fosaprepitant: a 10-year review of efficacy and safety Oncologist 20 450-458
[3]
Carides A(2017)Aprepitant in pediatric patients using moderate and highly emetogenic protocols: a systematic review and meta-analyses of randomized controlled trials Br J Clin Pharmacol 83 1108-1117
[4]
Rapoport BL(2018)Intravenous fosaprepitant for the prevention of chemotherapy-induced vomiting in children: A double-blind, placebo-controlled, phase III randomized trial Pediatric Blood & Cancer 66 e27551-vv33
[5]
Schmoll HJ(2016)2016 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients Ann Oncol 27 v119-308
[6]
Zhang L(2017)2016 updated MASCC/ESMO consensus recommendations: prevention of nausea and vomiting following multiple-day chemotherapy, high-dose chemotherapy, and breakthrough nausea and vomiting Support Care Cancer 25 303-131
[7]
Warr D(2014)Aprepitant and fosaprepitant use in children and adolescents at an academic medical center J Pediatr Pharmacol Therapeut 19 127-198
[8]
Okumura LM(2011)Guideline for the classification of the acute emetogenic potential of antineoplastic medication in pediatric cancer patients Pediatr Blood Cancer 57 191-1501
[9]
D'Athayde Rodrigues F(2010)Two-sided Exact Tests and Matching Confidence Intervals for Discrete Data The R Journal 2 53-1073
[10]
Ferreira MAP(2011)Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with cisplatin therapy: randomized, double-blind study protocol--EASE J Clin Oncol 29 1495-394